Inari Medical, Inc. Sustainability Profile
Inari Medical, Inc., a leading innovator in the medical device industry, is headquartered in the United States, with significant operations across North America and Europe. Founded in 2011, the company has rapidly established itself as a key player in the treatment of venous diseases, particularly through its pioneering approaches to thrombectomy. Inari Medical's core products, including the ClotTriever and the FlowTriever systems, are designed to provide effective, minimally invasive solutions for the removal of blood clots. These devices stand out for their unique design and efficacy, significantly improving patient outcomes. With a strong market position, Inari Medical has achieved notable milestones, including rapid revenue growth and recognition for its commitment to advancing vascular care. The company continues to push the boundaries of innovation, solidifying its reputation as a trusted name in the medical device sector.
DitchCarbon Score
How does Inari Medical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Inari Medical, Inc.'s score of 37 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Inari Medical, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Stryker Corporation, which influences its climate commitments and reporting practices. While Inari Medical has not set its own reduction targets, it inherits sustainability initiatives from Stryker Corporation, which is actively engaged in climate action. Stryker has established science-based targets through the Science Based Targets initiative (SBTi) and participates in the Carbon Disclosure Project (CDP), reflecting a commitment to reducing its carbon footprint across its operations. As a subsidiary, Inari Medical aligns with Stryker's broader sustainability goals, although specific emissions data and reduction targets for Inari Medical itself are not available. The company is expected to contribute to the overarching climate strategies set by its parent organisation, focusing on reducing Scope 1, 2, and potentially Scope 3 emissions as part of Stryker's comprehensive approach to environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 27,076,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 146,705,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
How Carbon Intensive is Inari Medical, Inc.'s Industry?
How Carbon Intensive is Inari Medical, Inc.'s Location?
Inari Medical, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Inari Medical, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
